Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Authors

Laurent Peyrin–Biroulet

Published

July 17, 2024

Abstract

The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown.

Supporters

Support the authors with ResearchCoin

Journal

New England Journal of Medicine

Topics

DOI

10.1056/nejmoa2314585

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Authors

Laurent Peyrin–Biroulet

Published

July 17, 2024

Abstract

The efficacy and safety of risankizumab as compared with ustekinumab in patients with Crohn's disease are unknown.

Supporters

Support the authors with ResearchCoin

Journal

New England Journal of Medicine

Topics

DOI

10.1056/nejmoa2314585

Paper

Paper

Paper

Paper

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Abstract

Supporters

Journal

Topics

DOI

Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

Abstract

Supporters

Journal

Topics

DOI